BioSpace News Archive

HealthLynked Corp. (OTCQB: HLYK), a global healthcare network focused on care management of its members and a provider of healthcare technologies that connects doctors, patients and medical data, reported its financial results late Friday for the three and six months ended June 30, 202

Neuroptika, a privately held biotechnology company focused on the development of novel regenerative treatments for ophthalmic diseases, today announced completion of enrollment in a Phase 2 clinical controlled, double-masked trial of NRO-1 for the treatment of patients with dry eye disease. NRO-1 is a novel therapeutic with the po

BVI, the fastest growing diversified company in ophthalmology, has entered the US intraocular lens (IOL) market with IPure, the first and only pre-loaded aspheric monofocal IOL available in both a 1-Piece and 3-Piece design for patients undergoing cataract surgery.

- MAU868 has the potential to be the first therapeutic to prevent and treat BKV-associated diseases in transplant patients

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the acceptance of the Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for Evrysdi™ (risdiplam) for the treatment of spinal muscular atrophy (SMA).

Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced the appointment of Daniel Messina , an experienced and well regarded health services executive and entrepreneur, to its Board of Directors, effective Au

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will webcast its Annual Meeting of Stockholders on Thursday, September 10, 2020, at 10:00 a.m. ET (5:00 p.m. Israel time) at 12 Leshem Street, Kiryat Gat, 8258412, Israel. During the meeting, Julian Adams, Ph.D., Gamida Cell’s chief executive officer, will present an overview o

Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease received approval from FDA of an investigational device exemption, or IDE, to start the TRIOMPHE study on the NEXUS™ Aortic Arch Stent Graft System (hereinafter referred to as NEXUS TM ). Earlier this year, FDA granted NEXUS TM designation as a breakthrough device. This designation acknowledges the NEXUS TM may provide a more effective trea

Combination of technology, services, and data supports more cost-effective workflows

— GAIN Trial enrollment on track to complete in Q4 2020 — GAIN Trial interim analysis on schedule to complete by year end 2020 — Clinical pipeline expansion anticipated in 2021